Activity Overview
This educational activity is an archive of the live conference held from February 26, 2026, through February 28, 2026.
Target Audience
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Evaluate recent clinical trial results on approved and emerging therapeutic approaches for patients with hematologic disorders
- Describe best practices for mitigating and managing treatment-related adverse events in patients with hematologic disorders
Naval G. Daver, MD
Professor of Medicine
Co-Lead, Section of AML
Director, Leukemia Research Alliance Program
Department of Leukemia, Division of Cancer
Medicine
The University of Texas MD Anderson Cancer
Center
Houston, TX
Gabriela Hobbs, MD
Associate
Professor
Harvard
Medical School
Clinical
Director, Leukemia Service
Massachusetts
General Hospital
Boston, MA
Hagop M. Kantarjian, MD
Professor,
Department of Leukemia
Samsung
Distinguished Leukemia Chair in Cancer Medicine
The
University of Texas MD Anderson Cancer Center
Houston, TX
Naveen Pemmaraju, MD
Professor,
Department of Leukemia
Director,
Blastic Plasmacytoid Dendritic Cell Neoplasm
Executive
Director, MDACC Cancer Network for Cancer Medicine
The
University of Texas MD Anderson Cancer Center
Houston,
TX
Please click here to view disclosures for faculty and the staff of Physicians’ Education Resource®.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
